21 CFR Part 11: Where Are We Now?

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-11-01-2003
Volume 2003 Supplement
Issue 5

FDA's revised guidance on 21 CFR Part 11 offers relief to the regulated industry by providing for enforcement discretion and suggesting a risk-based approach to compliance.

Recent Videos
Roger Viney, PhD, chief commercial officer for ICE Pharma
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Christian Dunne, director of Global Corporate Business Development at ChargePoint Technology
Drug Digest: Focusing on Solid Dosage Trends and Demand
Behind the Headlines, episode 7
Related Content